X
Vertex and NHS close in on cystic fibrosis drug pricing deal
https://pharmaphorum.com/news/vertex-and-nhs-closing-in-on-cf-drug-pricing-deal/
Rare diseases
Key payer backs Ultragenyx’ rare rickets drug at $200,000 per year
Express Scripts’ Miller backs “responsible” price
GSK sells rare disease drugs, including groundbreaking Strimvelis
CEO Walmsley opts to focus on blockbuster medicines
Takeda looks for loans to fund $40bn Shire takeover
CEO Weber wants to turn Takeda into global pharma
Alexion bids $855m for rare disease biotech Wilson Therapeutics
Wilson’s board has unanimously accepted the offer
How Will Spark’s Approval Impact the Gene Therapy Field?
Gene Therapy for Rare Disorders Summit
